Source:http://linkedlifedata.com/resource/pubmed/id/17168427
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
2006-12-15
|
pubmed:abstractText |
According to the USA Food and Drug Administration, quality of life (QOL) and/or survival are a priority for new anticancer drug approval. This study was performed to review approaches to QOL in randomized controlled clinical trials (RCCTs) and to survey the use of such measures in trials.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0300-8916
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
92
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
373-8
|
pubmed:dateRevised |
2008-12-12
|
pubmed:meshHeading | |
pubmed:articleTitle |
Quality of life assessment of randomized controlled trials.
|
pubmed:affiliation |
Department of Medical Oncology, Infermi Hospital, Rimini, Italy. ipanzini@auslrn.net
|
pubmed:publicationType |
Journal Article,
Review
|